scholarly journals Patients with Arthritis Undergoing Surgery: How Should We Manage Tumour Necrosis Factor Blocking Agents Perioperatively?-A Systematic Literature Review

2013 ◽  
Vol 54 (1) ◽  
pp. 253 ◽  
Author(s):  
Herwig Pieringer ◽  
Kathrin Danninger ◽  
Nikolay Tzaribachev ◽  
Nikolaus Böhler ◽  
Erich Pohanka ◽  
...  
RMD Open ◽  
2020 ◽  
Vol 6 (2) ◽  
pp. e001227 ◽  
Author(s):  
Jasmin Beate Kuemmerle-Deschner ◽  
Raju Gautam ◽  
Aneesh Thomas George ◽  
Syed Raza ◽  
Kathleen Graham Lomax ◽  
...  

ObjectivesSeveral therapies are used for the treatment of rareautoinflammatory conditions like cryopyrin-associated periodic fever syndromes (CAPS), hyperimmunoglobulin Dsyndrome (HIDS)/mevalonate kinase deficiency (MKD) and tumour necrosis factor receptor-associated periodic syndrome (TRAPS). However, reviews reporting on treatment outcomes of these therapies are lacking.MethodsA systematic literature review was conducted using Embase, MEDLINE, MEDLINE-In Process and Cochrane databases to identify the randomised/non-randomised controlled trials (RCTs/non-RCTs) and real-world observational studies of CAPS, HIDS/MKD and TRAPS published as full-texts (January 2000–September 2017) or conference abstracts (January 2014–September 2017). Studies with data for ≥1 biologic were included. Studies with <5 patients were excluded.ResultsOf the 3 342 retrieved publications, 72 studies were included (CAPS, n=43; HIDS/MKD, n=9; TRAPS, n=7; studies with ≥2 cohorts, n=13). Most studies were full-text (n=56), published after 2010 (n=56) and real-world observational studies (n=58). Among included studies, four were RCTs (canakinumab, n=2 (CAPS, n=1; HIDS/MKD and TRAPS, n=1); rilonacept, n=1 (in CAPS); simvastatin, n=1 (in HIDS/MKD)). Canakinumab and anakinra were the most commonly used therapies for CAPS and HIDS/MKD, whereas etanercept, canakinumab and anakinra were the most common for TRAPS. The available evidence suggested the efficacy or effectiveness of canakinumab and anakinra in CAPS, HIDS/MKD and TRAPS, and of etanercept in TRAPS; asingle RCT demonstrated the efficacy of rilonacept in CAPS.ConclusionsCanakinumab, anakinra, etanercept and rilonacept were reported to be well tolerated; however, injection-site reactions were observed frequently with anakinra, rilonacept and etanercept. Data on the use of tocilizumab, infliximab and adalimumab in these conditions were limited; thus, further research is warranted.


Author(s):  
Francisco Isaac Fernandes Gomes ◽  
Maria Gerusa Brito Aragão ◽  
Francisco Cesar Barroso Barbosa ◽  
Mirna Marques Bezerra ◽  
Vicente de Paulo Teixeira Pinto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document